Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View

Rodolfo Montironi, Silvia Gasparrini, Alessia Cimadamore, Roberta Mazzucchelli, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Alberto Briganti, Marina Scarpelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

More than 95% of all carcinomas of the prostate are referred to as acinar, microacinar, usual, or conventional type. A minority have been classified as variants. Variants can vary in histologic appearance and divergent differentiation compared with usual acinar adenocarcinoma. Some variants constitute different types of carcinoma and are not adenocarcinomas. Variants that represent a challenge to diagnose include the deceptively benign-looking atrophic, pseudohyperplastic, microcystic, and foamy gland variants. The signet ring-like, pleomorphic giant cell, and sarcomatoid variants have worse prognosis than usual acinar adenocarcinoma. Some variants can occur after therapy, such endocrine and radiation therapy: squamous neoplasms, neuroendocrine tumors, sarcomatoid carcinoma (ie, carcinosarcoma), and pleomorphic giant cell variant. Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that often arises in later stages of castration-resistant prostate cancer. We review some of the main morphologic features of variants of epithelial and neuroendocrine tumors of the prostate. Variants that can be a challenge in making a final diagnosis include deceptively benign-looking forms. Others have a worse prognosis than the usual acinar adenocarcinoma. Some variants can be seen after therapy and some constitute different types of carcinoma arising in the prostate and are not adenocarcinomas. Several mechanisms are involved in neuroendocrine differentiation and may represent future therapeutic targets in advanced disease.

Original languageEnglish (US)
JournalEuropean Urology, Supplements
DOIs
StateAccepted/In press - 2017

Fingerprint

Neuroendocrine Tumors
Prostate
Adenocarcinoma
Carcinosarcoma
Prostatic Neoplasms
Giant Cells
Castration
Radiotherapy
Therapeutics
Pathologists
Carcinoma
Neoplasms

Keywords

  • Atrophic adenocarcinoma
  • Foamy gland adenocarcinoma
  • Microcystic adenocarcinoma
  • Neuroendocrine tumors
  • Pleomorphic giant cell variant
  • Pseudohyperplastic adenocarcinoma
  • Sarcomatoid carcinoma
  • Squamous neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. / Montironi, Rodolfo; Gasparrini, Silvia; Cimadamore, Alessia; Mazzucchelli, Roberta; Massari, Francesco; Cheng, Liang; Lopez-Beltran, Antonio; Briganti, Alberto; Scarpelli, Marina.

In: European Urology, Supplements, 2017.

Research output: Contribution to journalArticle

Montironi, R, Gasparrini, S, Cimadamore, A, Mazzucchelli, R, Massari, F, Cheng, L, Lopez-Beltran, A, Briganti, A & Scarpelli, M 2017, 'Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View', European Urology, Supplements. https://doi.org/10.1016/j.eursup.2017.08.010
Montironi, Rodolfo ; Gasparrini, Silvia ; Cimadamore, Alessia ; Mazzucchelli, Roberta ; Massari, Francesco ; Cheng, Liang ; Lopez-Beltran, Antonio ; Briganti, Alberto ; Scarpelli, Marina. / Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. In: European Urology, Supplements. 2017.
@article{8e7cfd5767a14126b83c4e185ed2f58a,
title = "Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View",
abstract = "More than 95{\%} of all carcinomas of the prostate are referred to as acinar, microacinar, usual, or conventional type. A minority have been classified as variants. Variants can vary in histologic appearance and divergent differentiation compared with usual acinar adenocarcinoma. Some variants constitute different types of carcinoma and are not adenocarcinomas. Variants that represent a challenge to diagnose include the deceptively benign-looking atrophic, pseudohyperplastic, microcystic, and foamy gland variants. The signet ring-like, pleomorphic giant cell, and sarcomatoid variants have worse prognosis than usual acinar adenocarcinoma. Some variants can occur after therapy, such endocrine and radiation therapy: squamous neoplasms, neuroendocrine tumors, sarcomatoid carcinoma (ie, carcinosarcoma), and pleomorphic giant cell variant. Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that often arises in later stages of castration-resistant prostate cancer. We review some of the main morphologic features of variants of epithelial and neuroendocrine tumors of the prostate. Variants that can be a challenge in making a final diagnosis include deceptively benign-looking forms. Others have a worse prognosis than the usual acinar adenocarcinoma. Some variants can be seen after therapy and some constitute different types of carcinoma arising in the prostate and are not adenocarcinomas. Several mechanisms are involved in neuroendocrine differentiation and may represent future therapeutic targets in advanced disease.",
keywords = "Atrophic adenocarcinoma, Foamy gland adenocarcinoma, Microcystic adenocarcinoma, Neuroendocrine tumors, Pleomorphic giant cell variant, Pseudohyperplastic adenocarcinoma, Sarcomatoid carcinoma, Squamous neoplasms",
author = "Rodolfo Montironi and Silvia Gasparrini and Alessia Cimadamore and Roberta Mazzucchelli and Francesco Massari and Liang Cheng and Antonio Lopez-Beltran and Alberto Briganti and Marina Scarpelli",
year = "2017",
doi = "10.1016/j.eursup.2017.08.010",
language = "English (US)",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",

}

TY - JOUR

T1 - Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View

AU - Montironi, Rodolfo

AU - Gasparrini, Silvia

AU - Cimadamore, Alessia

AU - Mazzucchelli, Roberta

AU - Massari, Francesco

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Briganti, Alberto

AU - Scarpelli, Marina

PY - 2017

Y1 - 2017

N2 - More than 95% of all carcinomas of the prostate are referred to as acinar, microacinar, usual, or conventional type. A minority have been classified as variants. Variants can vary in histologic appearance and divergent differentiation compared with usual acinar adenocarcinoma. Some variants constitute different types of carcinoma and are not adenocarcinomas. Variants that represent a challenge to diagnose include the deceptively benign-looking atrophic, pseudohyperplastic, microcystic, and foamy gland variants. The signet ring-like, pleomorphic giant cell, and sarcomatoid variants have worse prognosis than usual acinar adenocarcinoma. Some variants can occur after therapy, such endocrine and radiation therapy: squamous neoplasms, neuroendocrine tumors, sarcomatoid carcinoma (ie, carcinosarcoma), and pleomorphic giant cell variant. Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that often arises in later stages of castration-resistant prostate cancer. We review some of the main morphologic features of variants of epithelial and neuroendocrine tumors of the prostate. Variants that can be a challenge in making a final diagnosis include deceptively benign-looking forms. Others have a worse prognosis than the usual acinar adenocarcinoma. Some variants can be seen after therapy and some constitute different types of carcinoma arising in the prostate and are not adenocarcinomas. Several mechanisms are involved in neuroendocrine differentiation and may represent future therapeutic targets in advanced disease.

AB - More than 95% of all carcinomas of the prostate are referred to as acinar, microacinar, usual, or conventional type. A minority have been classified as variants. Variants can vary in histologic appearance and divergent differentiation compared with usual acinar adenocarcinoma. Some variants constitute different types of carcinoma and are not adenocarcinomas. Variants that represent a challenge to diagnose include the deceptively benign-looking atrophic, pseudohyperplastic, microcystic, and foamy gland variants. The signet ring-like, pleomorphic giant cell, and sarcomatoid variants have worse prognosis than usual acinar adenocarcinoma. Some variants can occur after therapy, such endocrine and radiation therapy: squamous neoplasms, neuroendocrine tumors, sarcomatoid carcinoma (ie, carcinosarcoma), and pleomorphic giant cell variant. Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that often arises in later stages of castration-resistant prostate cancer. We review some of the main morphologic features of variants of epithelial and neuroendocrine tumors of the prostate. Variants that can be a challenge in making a final diagnosis include deceptively benign-looking forms. Others have a worse prognosis than the usual acinar adenocarcinoma. Some variants can be seen after therapy and some constitute different types of carcinoma arising in the prostate and are not adenocarcinomas. Several mechanisms are involved in neuroendocrine differentiation and may represent future therapeutic targets in advanced disease.

KW - Atrophic adenocarcinoma

KW - Foamy gland adenocarcinoma

KW - Microcystic adenocarcinoma

KW - Neuroendocrine tumors

KW - Pleomorphic giant cell variant

KW - Pseudohyperplastic adenocarcinoma

KW - Sarcomatoid carcinoma

KW - Squamous neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85029590695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029590695&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2017.08.010

DO - 10.1016/j.eursup.2017.08.010

M3 - Article

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

ER -